US20120083676A1 - Fetal ecg monitoring - Google Patents

Fetal ecg monitoring Download PDF

Info

Publication number
US20120083676A1
US20120083676A1 US13/249,812 US201113249812A US2012083676A1 US 20120083676 A1 US20120083676 A1 US 20120083676A1 US 201113249812 A US201113249812 A US 201113249812A US 2012083676 A1 US2012083676 A1 US 2012083676A1
Authority
US
United States
Prior art keywords
electrodes
fetal
torso
ecg
disposed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/249,812
Inventor
Adam J. Wolfberg
Gari D. Clifford
Jay Ward
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
E-TROLZ Inc
Massachusetts Institute of Technology
Tufts Medical Center Inc
E Trolz Inc
Original Assignee
Massachusetts Institute of Technology
Tufts Medical Center Inc
E Trolz Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Institute of Technology, Tufts Medical Center Inc, E Trolz Inc filed Critical Massachusetts Institute of Technology
Priority to US13/249,812 priority Critical patent/US20120083676A1/en
Assigned to TUFTS MEDICAL CENTER, INC. reassignment TUFTS MEDICAL CENTER, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: WOLFBERG, ADAM J.
Assigned to MASSACHUSETTS INSTITUTE OF TECHNOLOGY reassignment MASSACHUSETTS INSTITUTE OF TECHNOLOGY ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CLIFFORD, GARI D.
Assigned to E-TROLZ, INC. reassignment E-TROLZ, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: WARD, JAY
Publication of US20120083676A1 publication Critical patent/US20120083676A1/en
Assigned to NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT reassignment NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT CONFIRMATORY LICENSE (SEE DOCUMENT FOR DETAILS). Assignors: TUFTS MEDICAL CENTER
Abandoned legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/24Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof
    • A61B5/316Modalities, i.e. specific diagnostic methods
    • A61B5/318Heart-related electrical modalities, e.g. electrocardiography [ECG]
    • A61B5/344Foetal cardiography
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/41Detecting, measuring or recording for evaluating the immune or lymphatic systems
    • A61B5/412Detecting or monitoring sepsis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/43Detecting, measuring or recording for evaluating the reproductive systems
    • A61B5/4306Detecting, measuring or recording for evaluating the reproductive systems for evaluating the female reproductive systems, e.g. gynaecological evaluations
    • A61B5/4343Pregnancy and labour monitoring, e.g. for labour onset detection
    • A61B5/4362Assessing foetal parameters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/02Detecting, measuring or recording pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography or electroauscultation; Heart catheters for measuring blood pressure
    • A61B5/024Detecting, measuring or recording pulse rate or heart rate
    • A61B5/02411Detecting, measuring or recording pulse rate or heart rate of foetuses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/02Detecting, measuring or recording pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography or electroauscultation; Heart catheters for measuring blood pressure
    • A61B5/024Detecting, measuring or recording pulse rate or heart rate
    • A61B5/0245Detecting, measuring or recording pulse rate or heart rate by using sensing means generating electric signals, i.e. ECG signals

Definitions

  • This specification relates to fetal ECG (fECG) monitoring.
  • Electrocardiogram (ECG) monitoring has been widely used on adult patients for detecting medical conditions, for example, abnormities associated with the heart.
  • Signals representing a patient's cardiac activities can be collected through a set of skin surface electrodes distributed over the patient's body, for example, attached to the patient's chest and limbs.
  • a fetal monitoring system in one aspect, includes a data acquisition system for acquiring signals including signals representing surface measurements of cardiac activity.
  • a signal analyzer is coupled to the data acquisition system and is configured to analyze the acquired signals to generate an output having at least an clinical indicator characterizing a clinical condition.
  • the signal analyzer includes a signal processor for extracting fetal electrocardiogram signals from the acquired electrical signals, and a clinical condition detector for performing a morphological analysis of the extracted fetal electrocardiogram signals, and based on a result of the morphological analysis, determining the clinical indicator.
  • An output system is provided for presenting a representation of the clinical indicator.
  • Embodiments of this aspect may include one or more of the following features.
  • the output system includes a display unit for generating a visual representation of the output of the signal analyzer.
  • the display unit includes, for example, a computer screen and/or a handheld device.
  • a wireless transmitter may be provided for transmitting the output of the signal analyzer to the handheld device.
  • the data acquisition system includes an electrode array having at least a plurality of electrodes attachable to a maternal abdominal region.
  • the electrode array may further include a second plurality of electrodes attachable to a maternal lumbar region, and potentially a third plurality of electrodes attachable to a maternal side region.
  • the pluralities of electrodes are positioned in a pre-determined arrangement on a garment.
  • the signal analyzer further includes a heart rate detector for determining a fetal heart rate from the acquired signals.
  • the output system is further configured for presenting a representation of the fetal heart rate determined by the signal analyzer.
  • the heart rate detector may be further configured for determining a degree of irregularity in the fetal heart rate.
  • the output system is further configured for presenting a waveform representation of the fetal electrocardiogram signals.
  • the clinical condition detector is further configured for determining a measure of morphological variation in the extracted fetal electrocardiogram signals.
  • the measure of morphological variation includes an entropy of a sequence of segment classifications.
  • the clinical indicator determined by the clinical condition detector includes an indicator of a fetal condition.
  • the clinical indicator determined by the clinical condition detector may include an indicator of at least one of chorioamnionitis, preeclampsia, inflammation, and infection.
  • a signal selection unit is coupled to the signal analyzer for selectively rejecting one or more of the acquired signals based on a quality of the acquired signals.
  • a fetal monitoring system in another aspect, includes a data acquisition system for acquiring signals including signals representing surface measurements of cardiac activity.
  • a signal analyzer is coupled to the data acquisition system and is configured to analyze the acquired signals, including: obtaining information characterizing a fetal orientation according to a cardiac dipole model; and determining the fetal orientation based on the obtained information.
  • An output system is provided for presenting a representation of the fetal orientation determined by the signal analyzer.
  • aspects can include one or more of the following.
  • Performing the morphological analysis includes determining a quantitative measure of morphological variation.
  • determining the measure of morphological variation includes characterizing segments of signals determined from the acquired electrical signals according to a group of classes, and determining a measure of variation in sequences of segment classifications.
  • the quantitative measure of morphological variation may include an entropy of a sequence of segment classifications.
  • Determining a clinical indicator includes determining an indicator of at least one of chorioamnionitis, preeclampsia, inflammation, and infection.
  • a method for fetal monitoring includes acquiring electrical signals from a plurality of electrodes. These electrodes include a plurality of electrodes applied to a maternal abdominal region. The electrical signals are analyzed, including obtaining information characterizing a muscle movement associated with uterine contraction. A characteristic of the uterine contraction (e.g., a frequency or a strength the contraction) is then determined based on the obtained information.
  • a characteristic of the uterine contraction e.g., a frequency or a strength the contraction
  • a medical apparatus is configured to acquiring signals from a plurality of electrodes and perform steps of the methods identified above.
  • software stored on a computer readable medium includes instructions for causing a computing system to receive data representing signals from a plurality of electrodes, and perform steps of the methods described above.
  • Some embodiments may have one or more of the following advantages.
  • FIG. 2 is a block diagram of one embodiment of the ECG analyzer of FIG. 1 .
  • FIG. 7 shows another example of electrode configuration.
  • FIG. 8B shows a waveform of fetal ECG extracted from the fetal-maternal mixture of FIG. 8A .
  • FIGS. 9A-9C show three exemplary classes of ECG waveforms, respectively.
  • the data acquisition system 130 collects electrical signals, for example, electric potentials in the form of fetal-maternal mixtures, through a set of electrodes 132 .
  • These electrodes 132 include a set of electrodes distributed over the maternal abdomen, lower back, and/or sides, from which one or more leads are formed to generate electrical signals.
  • a lead is generally defined in association with a combination (e.g., a pair) of electrodes, which can be associated with an imaginary line in the body along which electrical signals are measured.
  • a lead records the electrical signals produced by the heart (e.g., in the form of a voltage differential) from the corresponding combination of electrodes placed at specific points on the patient's body.
  • Two different leads may use one or more common electrodes and therefore the number of leads in an ECG system is not necessarily in direct proportion to the number of electrodes placed on the patient's body.
  • the electrodes 132 are placed relatively far away from the maternal heart to reduce the influence of maternal signal in the fetal-maternal mixtures.
  • the electrodes 132 may also include one or more electrodes placed on the maternal chest near the heart from which a maternal reference lead can be determined.
  • the arrangement of the electrodes on the patient's body and the definition of lead pattern are selected depending on the particular implementation, as is discussed later is this document.
  • the signals collected by the data acquisition system 130 are transmitted to an ECG analyzer 150 that first digitizes raw ECG signals (e.g., at a sampling rate of 1,000 Hz and a resolution of 16 bits) for subsequent processing and analysis.
  • the raw signals are transmitted over multiple independent channels, for example, each channel for a different lead.
  • a channel selection module 140 applies a channel selection algorithm that can discard certain channels of “weak” (low quality) signals to allow only “strong” (high quality) signals to be passed to the ECG analyzer 150 .
  • Some of the discarded channels contain primarily noise, for example, due to fetal position change or poor electrode conductivity (e.g., caused by the non-conductive gel used in an earlier ultrasound procedure). These channels are preferably rejected as the noise characteristics may not be amendable to the type of filtering technique designed for the system. Further discussion of the channel selection algorithm is provided in a later section.
  • an ECG analyzer 250 to obtain data of clinical significance from raw ECG signals, some embodiments of an ECG analyzer 250 include a pre-processor 251 that applies one or more filtering techniques (as will be discussed later) to generate processed ECG signals, for example, in the form of “clean” fetal ECG waveforms or metrics (i.e., parameters) of fetal-maternal ECG models. These processed signals are used by one or more analyzing modules, as described below.
  • the clinical condition detector 252 includes a feature extractor 253 for extracting characteristics of the ECG signals, such as heart rate variability, ECG morphology, and morphology classification and entropy, to assist clinical evaluation. These characteristics are then provided to a clinical condition evaluator 254 , which identifies specific ECG patterns that are correlated with events of clinical significance.
  • the clinical condition evaluator 254 may use a clinical model 255 to correlate electrophysiological behaviors (e.g., ECG patterns) of the fetus and/or the mother with statistical behaviors in large populations associated well-established medical conditions, such as chorioamnionitis, histopathologic chorioamnionitis, and clinical neonatal infection. The resulting correlation is used to determine the susceptibility of the patient (mother and/or fetus) to such conditions.
  • electrophysiological behaviors e.g., ECG patterns
  • the clinical condition evaluator 254 may have separate modules (e.g., a chorioamnionitis evaluator, an intrapartum fever evaluator), with each module providing a measure of a degree of the presence of a particular aspect of fetal and/or maternal distress.
  • Physicians may receive the outputs of the individual modules in confidence scores, for example, presented on a scale of 0 to 10 with “0” indicating no (or least) distress and “10” indicating the highest level of distress.
  • the individual scores can also be combined to form an evaluation of overall fetal distress level indicating the general health condition of the fetus.
  • the clinical condition evaluator 254 performs an automated diagnosis to identify medical conditions (e.g., using expert systems and/or human intervention) and/or to provide recommendation for follow-up procedures.
  • other clinical data such as pathologic evaluations of serum samples from the umbilical cord
  • high quality fetal ECG data can be obtained from the patient under a variety of clinical conditions (e.g., pregnant or in-labor).
  • the characteristics of the ECG data can be well preserved to enable clinical analysis that is otherwise unavailable using conventional techniques. Implementations of the feature extractor 253 and examples of clinical condition evaluator 254 are described in greater detail at a later section.
  • a second example of an analyzing module is a fetal orientation detector 256 that provides an estimate of fetal position within the mother.
  • fetal position may change during various stages of pregnancy and the pre-labor position can affect the way by which the mother will deliver and whether certain cautionary steps need to be taken.
  • the fetal position is used as part of the feature extraction procedure, or as part of the clinical evaluation procedure. For example, signal acquisition in certain fetal positions may result in characteristically distinct signals, for example, that exhibit higher signal-to-noise characteristics.
  • automated clinical determinations are made as a function of the fetal position, for example, being performed only in certain fetal positions.
  • An example of such a fetal position is a fetus with its back to the maternal abdominal wall, which may result in particularly high quality signals due to the short distance between the fetal heart and the surface electrodes.
  • the estimated fetal position is used to select electrodes in the channel selection module 140 .
  • the estimated fetal position is used to determine signal and/or model characteristics related to various electrodes, for example, to determine signal transmission characteristics between the signal source (e.g., fetal heart) and the electrodes.
  • analyzing modules implemented in the ECG analyzer 250 include a heart rate tracker 258 , a fetal ECG waveform extractor (not shown), and possibly other modules that associate user-determined statistics with clinical analysis.
  • the heart rate tracker 258 may provide a continuous output of fetal heart beat over time and automatically identify the occurrence of heart rate acceleration, deceleration, and certain types of irregularity that can be early manifestation of serious medical conditions such as cardiac arrhythmia.
  • FIG. 4 shows one example of a data display by which the outputs of various analyzing modules are presented to physicians, for example, on a computer screen or a handheld device.
  • This display includes multiple regions that respectively show, for example, a fetal ECG waveform along with observed fetal heart rate, a fetal orientation pointer, an overall fetal distress index, an entropy index, and possibly other indices.
  • changes in fetal position since the most recent examination (or over the entire course of pregnancy) are also presented, for example, by loading prior position data from a patient database.
  • each index has a predefined “alert” level (e.g., a score of 6 out of 10) beyond which special attention (e.g., follow-up procedures) is indicated.
  • the monitoring system 100 also allows physicians to view detailed data, for example, the statistics upon which a particular index value is determined, when there is a need.
  • ECG signals can be collected using invasive and/or non-invasive approaches with the electrodes 132 placed in a variety of arrangements.
  • the following description provides two examples of electrode configurations suitable for use with the monitoring system 100 of FIG. 1 .
  • a first electrode configuration of some embodiments of the data acquisition system 130 is shown.
  • the configuration is capable of simultaneously collecting fetal scalp electrode ECG data (“gold-standard” fetal data), maternal ECG data (“gold-standard” maternal data), and combined data (fetal-maternal mixture) from the maternal abdomen.
  • Fetal ECG data can be isolated from the combined data using the gold standard maternal data and can be further compared with the gold standard fetal data.
  • ECG signals are obtained using 32 adhesive electrodes, including: 3 maternal chest electrodes (producing a robust maternal gold standard reference), 28 abdominal and back electrodes (producing an over-complete set of maternal/fetal mixtures), and a fetal single scalp electrode inserted using an intra-uterine probe.
  • the single intra-uterine probe although not employed without indication, can be optionally used on a significant number of patients (e.g., in-labor patients).
  • This probe can provide a strong, low-noise, fetal ECG signal, and hence a “gold standard” with which to compare the extracted fetal ECG from the abdominal probes.
  • the three chest electrodes provide a strong maternal ECG representation with no (or negligible) fetal contamination.
  • these electrodes can either be dry electrodes (e.g., Orbital Research, Cleveland, Ohio) or commercial gel adhesive electrodes (e.g., Red Dot, 3M, St. Paul, Minn.).
  • the electrodes are mounted onto the maternal body using a mesh (or garment), which can stabilize electrodes and improve electrode-skin contact during examination.
  • FIG. 6 shows exemplary ECG waveforms detected using the above described data acquisition system. These waveforms include fetal ECG, fetal-maternal ECG, and maternal ECG obtained respectively from fetal scalp electrodes, abdominal electrodes, and chest electrodes.
  • a second electrode configuration of some embodiments of the data acquisition system 130 is shown.
  • a set of dry electrodes e.g., 32
  • a convenient elastic monitoring garment that is strapped around the maternal abdomen to allow the electrodes to be distributed in a predetermined arrangement over the abdomen, the back, and on the sides of the patient.
  • No fetal scalp electrode is necessary with this configuration.
  • This configuration provides a non-invasive means to monitor fECG signals yet still capable of providing a sufficient set of useful fECG signals regardless of the fetal status.
  • the electrode arrangement and the lead pattern by which electrical signals are collected can use conventional standards developed on adult patients.
  • One example of such a conventional standard makes use of a well-established 12-lead pattern, with each lead recording the electrical activity of the adult heart from a different perspective.
  • the signal of each lead can correlate with a different anatomical area of the heart, for example, to help identify acute coronary ischemia or injury.
  • Fetal ECG signals are contained in some or all of the lead signals and may be extracted using various data extraction and filtering methods (as will be described later).
  • the isolation of fetal signals from fetal-maternal mixtures can be difficult as the conventional standards were developed based on adult models without accounting for the influence of fetal presence and the resulting fetal-maternal mixtures can be either poorly characterized or contain very low fetal components relative to the predominant maternal signals.
  • the electrode arrangement and the lead pattern use a design that suits the particular need of fetal ECG monitoring.
  • FIG. 7 illustrates the placement of some electrodes in a side view, a back view, and a sectional view of the patient body.
  • the entire set of electrodes forms at least of a group of cross-body leads each of which generates electrical signals along an imaginary line across the body, for example, from back to front, or from left side to right side.
  • Some of these leads are each formed by a respective pair of electrodes, one being referred to as a collecting/positive electrode (e.g., E 1 ) and the other being referred to as a reference/negative electrode (e.g., R 1 ).
  • the corresponding lead signal (e.g., L 1 ) is obtained, for example, using a biomedical instrumentation amplifier that forms an amplified signal representing a voltage differential between the collecting electrode and the reference electrode.
  • the reference electrode is placed at the opposite side of the body to which the collecting electrode is attached.
  • some of the collecting electrodes are placed in the abdominal region while the corresponding reference electrode(s) are placed in the lumbar region.
  • some of the collecting electrodes can be placed in the left side of the body while the corresponding reference electrode(s) are placed in the right side of the body.
  • each lead does not necessarily use a different reference electrode.
  • some leads may be formed using collecting electrodes at various positions in the abdominal region against a single reference electrode in the lumbar region.
  • the reference electrodes and the collecting electrodes can be electrodes of different characteristics (for example, made from different materials, having different sizes, and/or exhibiting different levels of signal sensitivity) and be attached to the body using different attachment mechanisms (e.g., dry vs. wet).
  • the set of electrodes is coupled to a lead reconfiguration module that can dynamically adjust electrode paring, lead selection, and/or garment positioning based on feedback signals provided by the ECG analyzer 150 to account for, for example, fetal position changes, loss of electrode contact, and other events that may cause abrupt changes in certain electrode or lead signals.
  • the channel selection module 140 is configured to adaptively select channels of “strong” (high quality) signals and discards channels of “weak” signals. As some of the abdominal signals will contain primarily noise, preferably, these channels are discarded from processing.
  • One technique used by the channel selection unit 140 to select channels of useful signals is based on fusing multiple signal quality indices (SQI) derived from multiple ECG leads.
  • SQI signal quality indices
  • physiological SQIs are obtained by analyzing the statistical characteristics of each channel and their relationships to each other. For instance, by computing spectral coherence, statistical departures from Gaussianity, and the performance of differently-sensitive event detectors, this technique allows the automatic location of channels that contain useful signal, and discarding of those that contain primarily noise. Furthermore, a sliding scale of quality is available to enable the selection of different channels for different applications.
  • Some techniques to extract waveforms of fetal ECG signals from the fetal-maternal mixtures include signal processing and filtering techniques such as adaptive filtering (AF), nonlinear projective filtering (NLPF), neural networks, independent component analysis (ICA) and joint time-frequency analysis (JTFA).
  • AF adaptive filtering
  • NLPF nonlinear projective filtering
  • ICA independent component analysis
  • JTFA joint time-frequency analysis
  • One limitation of these techniques lies in their dependencies on the signal-to-noise ratio (SNR) of the data and sensitivity to the frequent artifacts that manifest during FECG acquisition.
  • SNR signal-to-noise ratio
  • Each technique may either perform an “in-band” filtering (removing frequency signals that are present in the fetal signal) or produce a phase distortion in the signal that has an unknown affect on the fECG morphology.
  • fetal ECG signals pass through multiple layers of media (e.g., the vernix caseosa) each of which may have very different electric properties and some may cause significant attenuation the fetal ECG signals collected from surface electrodes.
  • media e.g., the vernix caseosa
  • the propagation medium of the maternal body may be considered as a linear instantaneous medium.
  • the body surface recordings are hence a linear instantaneous projection of the cardiac sources and artifacts onto the axes of the recording electrode pairs. It is however known that the electrical impedance of the body volume conductor changes with respiration. Therefore despite its linearity, the propagation medium is time-varying and the body surface recordings are rather non-stationary.
  • One method to address the issue of fetal ECG distortion due to transmission through media of varying dielectric constants is to use a model of the fetal cardiac source to constrain the filtering and feature extraction process.
  • One technique applies a three-dimensional dynamic model to represent the electrical activity of the heart. More specifically, this model is based on a single dipole model of the heart and is later related to the body surface potentials through a linear model which accounts for the temporal movements and rotations of the cardiac dipole, together with a realistic ECG noise model.
  • FIG. 8A illustrates a typical mixture of maternal and fetal ECG.
  • Both the fetal and maternal peak heights appear to be modulated by some low-frequency component (including, e.g., respiration).
  • respiration including, e.g., respiration.
  • a fetus will “practice” respiration prior to birth, and this can lead to changes in intra-thoracic pressure.
  • FIG. 8B illustrates the same signal after maternal subtraction using a model-based Kalman Filter tracking method described above. Note that the respiratory-modulation of the R-peaks and other features of the fECG are preserved in the waveform. These subtle features are essential in performing accurate feature analysis, such as R-peak location (e.g., for heart rate variability evaluation of sepsis), ST-elevation analysis (e.g., for ischemia) and QT interval analysis (for pro-arrhythmic indications).
  • R-peak location e.g., for heart rate variability evaluation of sepsis
  • ST-elevation analysis e.g., for ischemia
  • QT interval analysis for pro-arrhythmic indications
  • the feature extractor 253 of FIG. 2 is able to identify characteristics of the waveforms that are associated with clinically relevant activities. Examples of ECG characteristics include heart rate variability, ECG morphology, and entropy. For instance, fECG signals may be grouped into different morphological classes, and each class may be further divided based on subtle morphological characteristics, based on which patterns of clinical relevance may be identified. Techniques of feature extraction are described in greater detail below in the following sections.
  • the feature extractor 253 does not need the “clean” fetal ECG waveforms in order to obtain features of interest.
  • the pre-processor 251 may process the raw ECG data to obtain metrics of ECG models or symbolization of ECG classification, based on which the feature extractor 150 may extract interesting features.
  • Heart rate variability can be an important quantitative marker of cardiovascular regulation by the autonomic nervous system.
  • Heart rate is generated by the intrinsic rhythm of the sinoatrial node in the heart, but constant input from the brainstem through a feedback loop in the autonomic nervous system closely modulates this rate.
  • At rest variation in heart rate arises predominantly from vagal tone governed by the vagus nerve nuclei.
  • this variation is affected by the interaction between vagal and sympathetic activity, as well as by central respiratory and motor centers and peripheral oscillations in blood pressure and respiration.
  • heart beat may be detected by cross-correlating the cardiac signal with a reference heart beat trace from data recorded using the fetal ECG.
  • the height of the cross-correlation peak (if it is not normalized) provides a measure of the strength of the signal and its similarity to the reference.
  • the position of the peak provided an accurate measure of the exact time the beat occurred.
  • the cross-correlation can be used to locate fetal heart beats in the data, which can then be “windowed” out into a series of individual heart beats.
  • the data is then subjected to a multivariate statistical analysis, and the results are used to group beats according to variations in the ensemble of heart beats. These data can be later used for the analysis of waveform morphology.
  • each segment is modeled using a parametric model (e.g., using a sum of displaced Gaussian components) and the distance between segments is based on a distance between the model parameters of the segments.
  • the characteristics of the identified groups are used to determine a measure of morphological variation.
  • the segments of the fECG are labeled, for example, with discrete labels from an alphabet of symbols (e.g., 5 arbitrary labels). Then a statistical measure is determined from the sequence of labels, for example, in a sliding window of the signal.
  • One measure of morphological variation is an entropy of a sample distribution of the labels.
  • the entropy of a finite state model of the sequence is used.
  • the segments are not necessarily deterministically labeled (relying on a probability measure for beats in each hidden class), and the entropy of a underlying (e.g., hidden) sequence of segment classes is computed, thereby avoiding a need to first determine an accurate series of class labels, which may require a “clean” estimate of the fECG signal.
  • ECG monitors and ICU monitoring devices that compare observed phenomena to standardized patterns representing pathophysiological conditions (ventricular tachycardia or ST-depression, for example)
  • some entropy-based approaches of the types described above do not necessarily assume a priori information about the ECG morphology.
  • Each morphological class is represented by a symbol, and various patterns of symbols in sequence may have clinical significance.
  • This analytic approach is suited for the fetal ECG data collected in the present system 100 , because with the exception of ST-segment analysis, there are no formal systems for fetal ECG evaluation.
  • independence from a priori information can be useful in fetal applications where the information may not be available, or may be highly variable based on factors such as fetal age.
  • model-based filtering is applied to the fECG signal, for example, prior to entropy-based analysis.
  • Gaussian based modeling as described in Clifford et al., “Model-based filtering, compression and classification of ECG,” International Journal of Bioelectromagnetism Vol. 7, No. 1, pp 158-161, 2005, and in U.S. Patent Publication 2007/0260151,“Method and Device for Filtering, Segmenting, Compressing and Classifying Oscillatory Signals,” published Nov. 8, 2007, are used in processing the fECG signals.
  • the classification based on these techniques is used in determining entropy measures as described in the Syed reference.
  • each class may be characterized by a range of model parameters for that class (e.g., by partitioning the space of parameters values) or each class be associated with a distribution of the model parameters for that class.
  • characteristics of ECG patterns are associated with events of clinical activity.
  • Some examples of such clinical applications includes using an entropy measure of a fECG signal as an indicator of an inflammation condition, or as an indicator of a cause of an inflammation condition, for example, an infection-based cause of inflammation.
  • the fECG waveforms of 30 recordings discovered a change in the morphology of the heart beat that occurs prior to the development of chorioamnionitis.
  • FIGS. 9A-9C illustrate three classes of QRS complexes classified from a 7-hour dataset collected from a woman who developed chorioamnionitis during labor.
  • FIG. 9D shows the occurrence of each beat during 10-minute intervals timed with respect to the onset of maternal fever of the same patient. Note the consistent appearance of class 1 ECG signals one hour prior to the development of fever.
  • Analyses of the fetal ECG waveforms also show that a measure of entropy—the degree of disorder in the similarity of the morphology of sequences the fetal heart beats—distinguishes those fetuses subject to intra-amniotic infection from those without exposure to infection.
  • FIGS. 10A and 10B illustrate respectively the HRV analysis and entropy analysis of 30 fetal ECG datasets from women with chorioamnionitis and women without infection.
  • FIG. 10A the distribution of fetal HRV for fetuses subjected to chorioamnionitis (e.g., exhibiting maternal fever symptom) is not easily distinguishable from that of fetuses in an uninfected intrauterine environment.
  • FIG. 10A illustrates the distribution of fetal HRV for fetuses subjected to chorioamnionitis (e.g., exhibiting maternal fever symptom) is not easily distinguishable from that of fetuses in an uninfected intrauterine environment.
  • FIG. 10A the distribution of fetal HRV for fetuses subjected to chorioamnionitis (e.g., exhibiting maternal fever symptom) is not easily distinguishable from that of fe
  • FIG. 10B shows that, when the entropy of the fetal ECG signal is calculated for the same set of fetal ECG data, fetuses subjected to chorioamnionitis are bimodally distributed with respect to entropy, whereas fetuses in an uninfected environment are essentially normally distributed.
  • an ECG waveform having a very low (e.g., 0) or very high (e.g., 4) entropy indicates a higher probability of developing chorioamnionitis.
  • the distributions of observed entropy measures in two known classes of patients are used to form a likelihood ratio test to classify a patient based on an observed entropy.
  • different patterns of electrophysiological behaviors can be correlated with medical conditions using specific biochemical markers of such conditions, e.g., markers of inflammation and brain injury measured from fetal umbilical cord collected from the patient.
  • Umbilical cord blood interleukin-6 for example, is significantly elevated in fetuses that develop sepsis compared with fetuses that do not develop sepsis.
  • Cord blood levels of IL-6 greater than 108.5 pg/ml are considered 95% sensitive and 100% specific for neonatal sepsis.
  • FIG. 11 shows an association between the morphologic entropy of the fetal ECG and fetal umbilical cord serum interleukin-8 (IL-8) levels.
  • IL-8 fetal umbilical cord serum interleukin-8
  • Increasing levels of IL-8 are correlated (e.g., having a substantially linear relationship) with increasing disorder in the fetal ECG morphology.
  • This correlation is that an in-utero fetal inflammation/infection is associated with quantitative changes in the fetal ECG, reflecting altered electrophysiological signaling at the level of the fetal brainstem, fetal myocardium, or both.
  • Another related application relates to using characteristics of ECG signals to discriminate between different possible causes of medical conditions.
  • Various causes of diseases may induce changes in ECG morphology through different mechanisms, which may in turn lead to distinguishable patterns in ECG morphologies.
  • infection which is one explanation for inflammation, may induce a morphological change in fetal ECG signals through brain stem and myocardium level; while preeclampsia (pregnancy-induced hypertension) is likely to affect the ECG morphologies through mechanism of placental failure.
  • preeclampsia pregnancy-induced hypertension
  • the various presentations of ECG morphologies can therefore be used as a basis for discriminating between different causes of certain diseases.
  • the feature extractor 253 performs signal analysis that is not necessarily related to ECG signals. For example, muscle signals are detected using the surface electrodes or conventional pressure sensors for contractions, and timing and intensity of uterine contractions are estimated. This approach has an advantage of providing a single monitoring device being applied to the mother, while providing multiple clinically-relevant signals.
  • the fetal monitoring system 100 may incorporate functions of other medical diagnostic tools to enhance fetal ECG detection and/or assist clinical evaluations.
  • a maternal reference signal can be obtained using other sensing modes, such as ultrasound, imaging, and blood pressure sensing, to facilitate fetal ECG extraction.
  • histological and pathological data of a patient can be assessed in conjunction with ECG data to detect inflammation and neuronal injury before the onset of permanent disability.

Abstract

A method for fetal monitoring includes acquiring electrical signals from a set of electrodes, for example, a set of surface electrodes applied to a maternal abdominal region. The electrical signals are analyzed, including by performing a morphological analysis of fetal electrocardiogram signals. A clinical indicator is then determined from a result of performing the morphological analysis.

Description

    CROSS-REFERENCE TO RELATED APPLICATIONS
  • This application claims the benefit of U.S. Provisional Application No. 61/045,055, titled “Fetal Monitoring System,” filed Apr. 15, 2008, and U.S. Provisional Application No. 61/100,807, titled “Fetal ECG Monitoring,” filed Sep. 29, 2008. The contents of the above applications are incorporated herein by references.
  • BACKGROUND
  • This specification relates to fetal ECG (fECG) monitoring.
  • Electrocardiogram (ECG) monitoring has been widely used on adult patients for detecting medical conditions, for example, abnormities associated with the heart. Signals representing a patient's cardiac activities can be collected through a set of skin surface electrodes distributed over the patient's body, for example, attached to the patient's chest and limbs.
  • Monitoring of fetal ECG can be difficult due to the co-existence of maternal and fetal signals in raw signals acquired from a patient, as well as the relatively low fetal signal level relative to the maternal signal and other noise sources. Some conventional approaches to collecting fetal ECG signals include placing a wire electrode onto the fetal scalp. Although the fetal scalp electrode may provide a relatively clean fetal signal, this procedure can only be performed under limited clinical circumstances (e.g., when a patient is in labor, has ruptured amniotic membranes, and has a dilated cervix) and thus may not be suitable for the vast majority of pregnant and laboring patients. The placement of the fetal scalp electrode may also present certain risks to fetal safety, as rare cases of fetal scalp abscess and newborn death have been reported.
  • SUMMARY
  • In one aspect, in general, a fetal monitoring system includes a data acquisition system for acquiring signals including signals representing surface measurements of cardiac activity. A signal analyzer is coupled to the data acquisition system and is configured to analyze the acquired signals to generate an output having at least an clinical indicator characterizing a clinical condition. The signal analyzer includes a signal processor for extracting fetal electrocardiogram signals from the acquired electrical signals, and a clinical condition detector for performing a morphological analysis of the extracted fetal electrocardiogram signals, and based on a result of the morphological analysis, determining the clinical indicator. An output system is provided for presenting a representation of the clinical indicator.
  • Embodiments of this aspect may include one or more of the following features.
  • The output system includes a display unit for generating a visual representation of the output of the signal analyzer. The display unit includes, for example, a computer screen and/or a handheld device. A wireless transmitter may be provided for transmitting the output of the signal analyzer to the handheld device.
  • The data acquisition system includes an electrode array having at least a plurality of electrodes attachable to a maternal abdominal region. The electrode array may further include a second plurality of electrodes attachable to a maternal lumbar region, and potentially a third plurality of electrodes attachable to a maternal side region. The pluralities of electrodes are positioned in a pre-determined arrangement on a garment.
  • The signal analyzer further includes a heart rate detector for determining a fetal heart rate from the acquired signals. The output system is further configured for presenting a representation of the fetal heart rate determined by the signal analyzer. The heart rate detector may be further configured for determining a degree of irregularity in the fetal heart rate.
  • The output system is further configured for presenting a waveform representation of the fetal electrocardiogram signals.
  • The clinical condition detector is further configured for determining a measure of morphological variation in the extracted fetal electrocardiogram signals. The measure of morphological variation includes an entropy of a sequence of segment classifications.
  • The clinical indicator determined by the clinical condition detector includes an indicator of a fetal condition. The clinical indicator determined by the clinical condition detector may include an indicator of at least one of chorioamnionitis, preeclampsia, inflammation, and infection.
  • A signal selection unit is coupled to the signal analyzer for selectively rejecting one or more of the acquired signals based on a quality of the acquired signals.
  • In another aspect, in general, a fetal monitoring system includes a data acquisition system for acquiring signals including signals representing surface measurements of cardiac activity. A signal analyzer is coupled to the data acquisition system and is configured to analyze the acquired signals, including: obtaining information characterizing a fetal orientation according to a cardiac dipole model; and determining the fetal orientation based on the obtained information. An output system is provided for presenting a representation of the fetal orientation determined by the signal analyzer.
  • In another aspect, in general, a method for fetal monitoring includes acquiring electrical signals from a set of electrodes. These electrodes include a set of electrodes applied to a maternal abdominal region. The electrical signals are analyzed, including by performing a morphological analysis of fetal electrocardiogram signals. A clinical indicator is then determined from a result of performing the morphological analysis.
  • Aspects can include one or more of the following.
  • Performing the morphological analysis includes determining a quantitative measure of morphological variation. For example, determining the measure of morphological variation includes characterizing segments of signals determined from the acquired electrical signals according to a group of classes, and determining a measure of variation in sequences of segment classifications. The quantitative measure of morphological variation may include an entropy of a sequence of segment classifications.
  • Determining a clinical indicator includes determining an indicator of a fetal condition.
  • Determining a clinical indicator includes determining an indicator of an inflammation condition.
  • Determining a clinical indicator includes determining an indicator of at least one of chorioamnionitis, preeclampsia, inflammation, and infection.
  • In another aspect, in general, a method for fetal monitoring includes acquiring electrical signals from a plurality of electrodes. These electrodes include a plurality of electrodes applied to a maternal abdominal region. The electrical signals are analyzed, including obtaining information characterizing a fetal orientation, for example, according to a cardiac dipole model. The fetal orientation, including, for example, fetal movement and fetal position, is then determined based on the obtained information.
  • In another aspect, in general, a method for fetal monitoring includes acquiring electrical signals from a plurality of electrodes. These electrodes include a plurality of electrodes applied to a maternal abdominal region. The electrical signals are analyzed, including obtaining information characterizing a muscle movement associated with uterine contraction. A characteristic of the uterine contraction (e.g., a frequency or a strength the contraction) is then determined based on the obtained information.
  • In other aspects, in general, a medical apparatus is configured to acquiring signals from a plurality of electrodes and perform steps of the methods identified above.
  • In another aspect, in general, software stored on a computer readable medium includes instructions for causing a computing system to receive data representing signals from a plurality of electrodes, and perform steps of the methods described above.
  • Some embodiments may have one or more of the following advantages.
  • In some embodiments, morphologic entropy in fetal ECG signals is used as a risk metric for early detection of inflammation and neuronal injury during pregnancy, for example, due to conditions such as intrauterine infection that are associated with an increased risk of cerebral palsy and sepsis in newborns. Early detection of inflammation may allow for interventions that can reduce the risk of adverse new born outcome.
  • In some examples, morphologic entropy of the fetal ECG signal is measured using an unsupervised algorithm to first partition heart beats into different classes of activity based on their morphology, and then to compute the entropy of the symbolic sequence obtained by replacing each beat in the original signal with a label corresponding to its morphologic class. When evaluated on fetal ECG recordings, morphologic entropy shows a statistically significant correlation (e.g., a substantially linear association) with the level of certain biochemical marker (e.g., interleukin-8) in umbilical cord serum. This may provide a noninvasive means to detect inflammation and neuronal injury before the onset of permanent disability, thereby facilitating clinical intervention.
  • Other features and advantages are apparent from the following description, and from the claims.
  • DESCRIPTION OF DRAWINGS
  • FIG. 1 is a block diagram of one embodiment of a fetal monitoring system.
  • FIG. 2 is a block diagram of one embodiment of the ECG analyzer of FIG. 1.
  • FIGS. 3A-3C illustrate fetal position changes during pregnancy.
  • FIG. 4 shows an example of data display of the fetal monitoring system of FIG. 1.
  • FIG. 5 shows one example of electrode configuration.
  • FIG. 6 shows ECG waveforms collected using the electrode configuration of FIG. 5.
  • FIG. 7 shows another example of electrode configuration.
  • FIG. 8A shows a waveform of fetal-maternal mixture.
  • FIG. 8B shows a waveform of fetal ECG extracted from the fetal-maternal mixture of FIG. 8A.
  • FIGS. 9A-9C show three exemplary classes of ECG waveforms, respectively.
  • FIG. 9D shows the occurrence of different classes of ECG waveforms in one patient with respect to time.
  • FIG. 10A illustrates the distribution of heart rate variability among fever and normal populations.
  • FIG. 10B illustrates the distribution of ECG entropy among fever and normal populations.
  • FIG. 11C illustrates a correlation between ECG entropy and IL-8 level.
  • DETAILED DESCRIPTION Overview
  • Referring to FIG. 1, in some embodiments, a fetal monitoring system 100 is configured to identify characteristics of fetal ECG (fECG) signals collected from a patient 110 and based on these characteristics to detect events of clinical significance, including, for example, predicting impending fetal injury caused by inflammatory, hypoxic, or ischemic insults.
  • Very generally, the fetal monitoring system 100 includes an ECG monitor 120 that obtains and analyzes fetal ECG signals to generate data of clinical relevance. In some embodiments, the ECG monitor 120 makes use of morphological information in the fECG signal in addition to or instead of solely determining heart rate information. Data generated by the ECG monitor 120 can be presented to physicians in a variety of forms, for example, as printed on paper charts, shown on a display unit 160 (e.g., a computer screen), and transmitted via wireless signals to a handheld device 170 (e.g., a smart phone or PDA).
  • In this example, the ECG monitor 120 includes a data acquisition system 130, a channel selection module 140 (optional), and an ECG analyzer 150.
  • The data acquisition system 130 collects electrical signals, for example, electric potentials in the form of fetal-maternal mixtures, through a set of electrodes 132. These electrodes 132 include a set of electrodes distributed over the maternal abdomen, lower back, and/or sides, from which one or more leads are formed to generate electrical signals.
  • In this description, a lead is generally defined in association with a combination (e.g., a pair) of electrodes, which can be associated with an imaginary line in the body along which electrical signals are measured. A lead records the electrical signals produced by the heart (e.g., in the form of a voltage differential) from the corresponding combination of electrodes placed at specific points on the patient's body. Two different leads may use one or more common electrodes and therefore the number of leads in an ECG system is not necessarily in direct proportion to the number of electrodes placed on the patient's body. In some examples, the electrodes 132 are placed relatively far away from the maternal heart to reduce the influence of maternal signal in the fetal-maternal mixtures. In some other examples, the electrodes 132 may also include one or more electrodes placed on the maternal chest near the heart from which a maternal reference lead can be determined. The arrangement of the electrodes on the patient's body and the definition of lead pattern are selected depending on the particular implementation, as is discussed later is this document.
  • The signals collected by the data acquisition system 130 are transmitted to an ECG analyzer 150 that first digitizes raw ECG signals (e.g., at a sampling rate of 1,000 Hz and a resolution of 16 bits) for subsequent processing and analysis. In some examples, the raw signals are transmitted over multiple independent channels, for example, each channel for a different lead. In this example, a channel selection module 140 applies a channel selection algorithm that can discard certain channels of “weak” (low quality) signals to allow only “strong” (high quality) signals to be passed to the ECG analyzer 150. Some of the discarded channels contain primarily noise, for example, due to fetal position change or poor electrode conductivity (e.g., caused by the non-conductive gel used in an earlier ultrasound procedure). These channels are preferably rejected as the noise characteristics may not be amendable to the type of filtering technique designed for the system. Further discussion of the channel selection algorithm is provided in a later section.
  • Referring to FIG. 2, to obtain data of clinical significance from raw ECG signals, some embodiments of an ECG analyzer 250 include a pre-processor 251 that applies one or more filtering techniques (as will be discussed later) to generate processed ECG signals, for example, in the form of “clean” fetal ECG waveforms or metrics (i.e., parameters) of fetal-maternal ECG models. These processed signals are used by one or more analyzing modules, as described below.
  • 1.1 Clinical Condition Detector
  • One example of a type of an analyzing module is a clinical condition detector 252. Very generally, the clinical condition detector 252 includes a feature extractor 253 for extracting characteristics of the ECG signals, such as heart rate variability, ECG morphology, and morphology classification and entropy, to assist clinical evaluation. These characteristics are then provided to a clinical condition evaluator 254, which identifies specific ECG patterns that are correlated with events of clinical significance. For example, the clinical condition evaluator 254 may use a clinical model 255 to correlate electrophysiological behaviors (e.g., ECG patterns) of the fetus and/or the mother with statistical behaviors in large populations associated well-established medical conditions, such as chorioamnionitis, histopathologic chorioamnionitis, and clinical neonatal infection. The resulting correlation is used to determine the susceptibility of the patient (mother and/or fetus) to such conditions. Depending on the particular implementation, the clinical condition evaluator 254 may have separate modules (e.g., a chorioamnionitis evaluator, an intrapartum fever evaluator), with each module providing a measure of a degree of the presence of a particular aspect of fetal and/or maternal distress. Physicians may receive the outputs of the individual modules in confidence scores, for example, presented on a scale of 0 to 10 with “0” indicating no (or least) distress and “10” indicating the highest level of distress. The individual scores can also be combined to form an evaluation of overall fetal distress level indicating the general health condition of the fetus.
  • In some embodiments, the clinical condition evaluator 254 performs an automated diagnosis to identify medical conditions (e.g., using expert systems and/or human intervention) and/or to provide recommendation for follow-up procedures. In some examples, other clinical data (such as pathologic evaluations of serum samples from the umbilical cord) are collected from the patient in pregnancy or during labor and are used by the clinical condition evaluator 254 in conjunction with the identified ECG characteristics to help further determine the likelihood of impending fetal/neonatal injuries (such as brain injuries, cerebral palsy, and death).
  • Using the feature extractor 253, high quality fetal ECG data can be obtained from the patient under a variety of clinical conditions (e.g., pregnant or in-labor). The characteristics of the ECG data can be well preserved to enable clinical analysis that is otherwise unavailable using conventional techniques. Implementations of the feature extractor 253 and examples of clinical condition evaluator 254 are described in greater detail at a later section.
  • 1.2 Fetal Orientation Detector
  • A second example of an analyzing module is a fetal orientation detector 256 that provides an estimate of fetal position within the mother.
  • Referring to FIGS. 3A-3C, fetal position may change during various stages of pregnancy and the pre-labor position can affect the way by which the mother will deliver and whether certain cautionary steps need to be taken. In some applications, it is desirable to generate an estimate of fetal position as an output of the monitoring system, for example, providing a clinician with a continuous output.
  • In some examples, such a position estimate is determined as part of a multiple dipole modeling approach for extracting the fECG signal from the raw signals that include both fetal and maternal signals, in which estimated orientation of the dipole of the fetal heart provides an estimate of the orientation of the fetus relative to the mother's body.
  • In some examples, the fetal position is used as part of the feature extraction procedure, or as part of the clinical evaluation procedure. For example, signal acquisition in certain fetal positions may result in characteristically distinct signals, for example, that exhibit higher signal-to-noise characteristics. In some examples, automated clinical determinations are made as a function of the fetal position, for example, being performed only in certain fetal positions. An example of such a fetal position is a fetus with its back to the maternal abdominal wall, which may result in particularly high quality signals due to the short distance between the fetal heart and the surface electrodes. In some examples, the estimated fetal position is used to select electrodes in the channel selection module 140. In some examples, the estimated fetal position is used to determine signal and/or model characteristics related to various electrodes, for example, to determine signal transmission characteristics between the signal source (e.g., fetal heart) and the electrodes.
  • Other examples of analyzing modules implemented in the ECG analyzer 250 include a heart rate tracker 258, a fetal ECG waveform extractor (not shown), and possibly other modules that associate user-determined statistics with clinical analysis. The heart rate tracker 258 may provide a continuous output of fetal heart beat over time and automatically identify the occurrence of heart rate acceleration, deceleration, and certain types of irregularity that can be early manifestation of serious medical conditions such as cardiac arrhythmia.
  • Note that the pre-processor 250 may provide signals to various analyzing modules in different forms. In other words, the input data to the clinical condition detector 252 is not necessarily the same data provided to the orientation detector 256 or the heart rate tracker 258. Depending on the particular implementation, some analyzing modules may accept data representing “clean” fetal ECG waveforms, whereas others may accept data representing metrics of predefined fetal-maternal ECG models.
  • FIG. 4 shows one example of a data display by which the outputs of various analyzing modules are presented to physicians, for example, on a computer screen or a handheld device. This display includes multiple regions that respectively show, for example, a fetal ECG waveform along with observed fetal heart rate, a fetal orientation pointer, an overall fetal distress index, an entropy index, and possibly other indices. In some examples, changes in fetal position since the most recent examination (or over the entire course of pregnancy) are also presented, for example, by loading prior position data from a patient database. In some examples, each index has a predefined “alert” level (e.g., a score of 6 out of 10) beyond which special attention (e.g., follow-up procedures) is indicated. In some examples, the monitoring system 100 also allows physicians to view detailed data, for example, the statistics upon which a particular index value is determined, when there is a need.
  • Electrode Configuration
  • Depending on the particular implementation, ECG signals can be collected using invasive and/or non-invasive approaches with the electrodes 132 placed in a variety of arrangements. The following description provides two examples of electrode configurations suitable for use with the monitoring system 100 of FIG. 1.
  • 2.1 Example I
  • Referring to FIG. 5, a first electrode configuration of some embodiments of the data acquisition system 130 is shown. In this example, the configuration is capable of simultaneously collecting fetal scalp electrode ECG data (“gold-standard” fetal data), maternal ECG data (“gold-standard” maternal data), and combined data (fetal-maternal mixture) from the maternal abdomen. Fetal ECG data can be isolated from the combined data using the gold standard maternal data and can be further compared with the gold standard fetal data.
  • In this example, ECG signals are obtained using 32 adhesive electrodes, including: 3 maternal chest electrodes (producing a robust maternal gold standard reference), 28 abdominal and back electrodes (producing an over-complete set of maternal/fetal mixtures), and a fetal single scalp electrode inserted using an intra-uterine probe. The single intra-uterine probe, although not employed without indication, can be optionally used on a significant number of patients (e.g., in-labor patients). This probe can provide a strong, low-noise, fetal ECG signal, and hence a “gold standard” with which to compare the extracted fetal ECG from the abdominal probes. The three chest electrodes provide a strong maternal ECG representation with no (or negligible) fetal contamination. Using the chest and scalp electrodes, the quality of both the maternal removal and the fetal extraction can be evaluated. Depending on implementation, these electrodes can either be dry electrodes (e.g., Orbital Research, Cleveland, Ohio) or commercial gel adhesive electrodes (e.g., Red Dot, 3M, St. Paul, Minn.). In some examples, the electrodes are mounted onto the maternal body using a mesh (or garment), which can stabilize electrodes and improve electrode-skin contact during examination.
  • FIG. 6 shows exemplary ECG waveforms detected using the above described data acquisition system. These waveforms include fetal ECG, fetal-maternal ECG, and maternal ECG obtained respectively from fetal scalp electrodes, abdominal electrodes, and chest electrodes.
  • 2.2 Example II
  • Referring to FIG. 7, a second electrode configuration of some embodiments of the data acquisition system 130 is shown. Here, a set of dry electrodes (e.g., 32) are mounted on a convenient elastic monitoring garment that is strapped around the maternal abdomen to allow the electrodes to be distributed in a predetermined arrangement over the abdomen, the back, and on the sides of the patient. No fetal scalp electrode is necessary with this configuration. This configuration provides a non-invasive means to monitor fECG signals yet still capable of providing a sufficient set of useful fECG signals regardless of the fetal status.
  • In some embodiments, the electrode arrangement and the lead pattern by which electrical signals are collected can use conventional standards developed on adult patients. One example of such a conventional standard makes use of a well-established 12-lead pattern, with each lead recording the electrical activity of the adult heart from a different perspective. The signal of each lead can correlate with a different anatomical area of the heart, for example, to help identify acute coronary ischemia or injury. Fetal ECG signals are contained in some or all of the lead signals and may be extracted using various data extraction and filtering methods (as will be described later). In some cases, the isolation of fetal signals from fetal-maternal mixtures can be difficult as the conventional standards were developed based on adult models without accounting for the influence of fetal presence and the resulting fetal-maternal mixtures can be either poorly characterized or contain very low fetal components relative to the predominant maternal signals.
  • In some other embodiments, the electrode arrangement and the lead pattern use a design that suits the particular need of fetal ECG monitoring. One example of the design is shown in FIG. 7, which illustrates the placement of some electrodes in a side view, a back view, and a sectional view of the patient body. In this example, the entire set of electrodes forms at least of a group of cross-body leads each of which generates electrical signals along an imaginary line across the body, for example, from back to front, or from left side to right side. Some of these leads are each formed by a respective pair of electrodes, one being referred to as a collecting/positive electrode (e.g., E1) and the other being referred to as a reference/negative electrode (e.g., R1). The corresponding lead signal (e.g., L1) is obtained, for example, using a biomedical instrumentation amplifier that forms an amplified signal representing a voltage differential between the collecting electrode and the reference electrode. For some of these leads, the reference electrode is placed at the opposite side of the body to which the collecting electrode is attached. For example, some of the collecting electrodes are placed in the abdominal region while the corresponding reference electrode(s) are placed in the lumbar region. Similarly, some of the collecting electrodes can be placed in the left side of the body while the corresponding reference electrode(s) are placed in the right side of the body.
  • Using such a lead pattern, some of the collected signals can exhibit a stronger fetal component and/or contain less noise compared with lead signals collected using conventional adult standards. Depending on the particular implementation, each lead does not necessarily use a different reference electrode. In other words, some leads may be formed using collecting electrodes at various positions in the abdominal region against a single reference electrode in the lumbar region. In some examples, the reference electrodes and the collecting electrodes can be electrodes of different characteristics (for example, made from different materials, having different sizes, and/or exhibiting different levels of signal sensitivity) and be attached to the body using different attachment mechanisms (e.g., dry vs. wet). In some examples, the set of electrodes is coupled to a lead reconfiguration module that can dynamically adjust electrode paring, lead selection, and/or garment positioning based on feedback signals provided by the ECG analyzer 150 to account for, for example, fetal position changes, loss of electrode contact, and other events that may cause abrupt changes in certain electrode or lead signals.
  • Channel Selection
  • In the exemplary electrode configurations shown in FIGS. 5 and 7, one reason to record a large number of abdominal and back signals described above is that the fetal ECG tends to manifest in only a subset of these leads, yet the actual combination is dependent on the state of the fetus, the time through pregnancy, the degree of electrical contact, and the location and orientation of the fetus or fetuses. Therefore, the channel selection module 140 is configured to adaptively select channels of “strong” (high quality) signals and discards channels of “weak” signals. As some of the abdominal signals will contain primarily noise, preferably, these channels are discarded from processing.
  • One technique used by the channel selection unit 140 to select channels of useful signals is based on fusing multiple signal quality indices (SQI) derived from multiple ECG leads. In some examples, physiological SQIs are obtained by analyzing the statistical characteristics of each channel and their relationships to each other. For instance, by computing spectral coherence, statistical departures from Gaussianity, and the performance of differently-sensitive event detectors, this technique allows the automatic location of channels that contain useful signal, and discarding of those that contain primarily noise. Furthermore, a sliding scale of quality is available to enable the selection of different channels for different applications. Further discussion of this technique is provided by Li et al., in “Robust Heart Rate Estimation from Multiple Asynchronous Noisy Sources Using Signal Quality Indices and a Kalman Filter,” published in Physiological Measurement 29 (2008) 15-32, the disclosure of which is incorporated herein by reference.
  • 4 Extraction of Fetal Signals from Fetal-Maternal Mixtures
  • Some techniques to extract waveforms of fetal ECG signals from the fetal-maternal mixtures include signal processing and filtering techniques such as adaptive filtering (AF), nonlinear projective filtering (NLPF), neural networks, independent component analysis (ICA) and joint time-frequency analysis (JTFA). One limitation of these techniques lies in their dependencies on the signal-to-noise ratio (SNR) of the data and sensitivity to the frequent artifacts that manifest during FECG acquisition. Each technique may either perform an “in-band” filtering (removing frequency signals that are present in the fetal signal) or produce a phase distortion in the signal that has an unknown affect on the fECG morphology. These issues may result in significant changes in the clinical parameters one wishes to extract from the fECG.
  • Another issue in fetal ECG recording and analysis deals with signal distortions that result from the transmission of the fetal signal trough the mother's abdomen. To reach the surface electrodes, fECG signals pass through multiple layers of media (e.g., the vernix caseosa) each of which may have very different electric properties and some may cause significant attenuation the fetal ECG signals collected from surface electrodes. Since the effective frequency range of the ECG is below 1-2 KHz and considering the distance between the body surface electrodes and the cardiac sources, the propagation medium of the maternal body may be considered as a linear instantaneous medium. The body surface recordings are hence a linear instantaneous projection of the cardiac sources and artifacts onto the axes of the recording electrode pairs. It is however known that the electrical impedance of the body volume conductor changes with respiration. Therefore despite its linearity, the propagation medium is time-varying and the body surface recordings are rather non-stationary.
  • One method to address the issue of fetal ECG distortion due to transmission through media of varying dielectric constants is to use a model of the fetal cardiac source to constrain the filtering and feature extraction process. One technique, for example, applies a three-dimensional dynamic model to represent the electrical activity of the heart. More specifically, this model is based on a single dipole model of the heart and is later related to the body surface potentials through a linear model which accounts for the temporal movements and rotations of the cardiac dipole, together with a realistic ECG noise model. Details of this technique are further described by Sameni et al., in “Multichannel ECG and Noise Modeling: Application to Maternal and Fetal ECG Signals,” published in EURASIP Journal on Advances in Signal Processing, Volume 2007, Article ID 43407, the disclosure of which is incorporated herein by reference.
  • FIG. 8A illustrates a typical mixture of maternal and fetal ECG. The maternal beats appear as negative spikes (HR=90 bpm), and the fetal beats appear as the smaller, positive spikes (HR=138 bpm). Both the fetal and maternal peak heights appear to be modulated by some low-frequency component (including, e.g., respiration). A fetus will “practice” respiration prior to birth, and this can lead to changes in intra-thoracic pressure.
  • FIG. 8B illustrates the same signal after maternal subtraction using a model-based Kalman Filter tracking method described above. Note that the respiratory-modulation of the R-peaks and other features of the fECG are preserved in the waveform. These subtle features are essential in performing accurate feature analysis, such as R-peak location (e.g., for heart rate variability evaluation of sepsis), ST-elevation analysis (e.g., for ischemia) and QT interval analysis (for pro-arrhythmic indications).
  • Using these “clean” fetal ECG waveforms, the feature extractor 253 of FIG. 2 is able to identify characteristics of the waveforms that are associated with clinically relevant activities. Examples of ECG characteristics include heart rate variability, ECG morphology, and entropy. For instance, fECG signals may be grouped into different morphological classes, and each class may be further divided based on subtle morphological characteristics, based on which patterns of clinical relevance may be identified. Techniques of feature extraction are described in greater detail below in the following sections.
  • In some examples, the feature extractor 253 does not need the “clean” fetal ECG waveforms in order to obtain features of interest. For instance, the pre-processor 251 may process the raw ECG data to obtain metrics of ECG models or symbolization of ECG classification, based on which the feature extractor 150 may extract interesting features.
  • 5. Feature Extraction and Clinical Analysis 5.1 Heart Rate Variability Analysis
  • Heart rate variability (HRV) can be an important quantitative marker of cardiovascular regulation by the autonomic nervous system. Heart rate is generated by the intrinsic rhythm of the sinoatrial node in the heart, but constant input from the brainstem through a feedback loop in the autonomic nervous system closely modulates this rate. At rest, variation in heart rate arises predominantly from vagal tone governed by the vagus nerve nuclei. However, this variation is affected by the interaction between vagal and sympathetic activity, as well as by central respiratory and motor centers and peripheral oscillations in blood pressure and respiration.
  • In many clinical settings, evaluation of HRV is based on the subjective interpretation of this variable by clinicians using paper printouts that plot the fetal heart rate as a function of time. In some embodiments, heart beat may be detected by cross-correlating the cardiac signal with a reference heart beat trace from data recorded using the fetal ECG. The height of the cross-correlation peak (if it is not normalized) provides a measure of the strength of the signal and its similarity to the reference. The position of the peak provided an accurate measure of the exact time the beat occurred. These measures provided a way to reject signal that is not a fetal beat as well as to measure accurately the time between beats (the fetal heart rate). This approach provides data that can be used for analyses based on rate and HRV.
  • The cross-correlation can be used to locate fetal heart beats in the data, which can then be “windowed” out into a series of individual heart beats. The data is then subjected to a multivariate statistical analysis, and the results are used to group beats according to variations in the ensemble of heart beats. These data can be later used for the analysis of waveform morphology.
  • 5.2 Morphological Analysis
  • In some embodiments, the feature extractor 253 performs morphological analysis on the fECG signal. One approach to analyzing fetal ECG morphology uses clustering and symbolic analysis of ECG signals to discover medically relevant patterns. Very generally, ECG signals are classified into groupings that are morphologically similar according to a signal waveform similarity measure. In some examples, successive segments of the fECG waveform are formed with one segment per beat, and min-max clustering is then used to form the groupings according to pair-wise distance between the waveform segments. In some embodiments, the pair-wise distance between segments uses a dynamic time-warping (DTW) measure. In other examples, each segment is modeled using a parametric model (e.g., using a sum of displaced Gaussian components) and the distance between segments is based on a distance between the model parameters of the segments. The characteristics of the identified groups are used to determine a measure of morphological variation. In some examples, the segments of the fECG are labeled, for example, with discrete labels from an alphabet of symbols (e.g., 5 arbitrary labels). Then a statistical measure is determined from the sequence of labels, for example, in a sliding window of the signal.
  • One measure of morphological variation is an entropy of a sample distribution of the labels. In some examples, the entropy of a finite state model of the sequence is used. In some examples, the segments are not necessarily deterministically labeled (relying on a probability measure for beats in each hidden class), and the entropy of a underlying (e.g., hidden) sequence of segment classes is computed, thereby avoiding a need to first determine an accurate series of class labels, which may require a “clean” estimate of the fECG signal. Some aspects of these approaches are described by Syed et al., in “Clustering and Symbolic Analysis of Cardiovascular Signals: Discovery and Visualization of Medically Relevant Patterns in Long-Term Data Using Limited Prior Knowledge,” published in EURASIP Journal on Advances in Signal Processing, Volume 2007, Article ID 67938, the disclosure of which is incorporated herein by reference.
  • Unlike the techniques incorporated into ECG monitors and ICU monitoring devices that compare observed phenomena to standardized patterns representing pathophysiological conditions (ventricular tachycardia or ST-depression, for example), some entropy-based approaches of the types described above do not necessarily assume a priori information about the ECG morphology. Each morphological class is represented by a symbol, and various patterns of symbols in sequence may have clinical significance. This analytic approach is suited for the fetal ECG data collected in the present system 100, because with the exception of ST-segment analysis, there are no formal systems for fetal ECG evaluation. Independence from a priori information can be useful in fetal applications where the information may not be available, or may be highly variable based on factors such as fetal age.
  • In some examples, model-based filtering is applied to the fECG signal, for example, prior to entropy-based analysis. For example, Gaussian based modeling as described in Clifford et al., “Model-based filtering, compression and classification of ECG,” International Journal of Bioelectromagnetism Vol. 7, No. 1, pp 158-161, 2005, and in U.S. Patent Publication 2007/0260151,“Method and Device for Filtering, Segmenting, Compressing and Classifying Oscillatory Signals,” published Nov. 8, 2007, are used in processing the fECG signals. These references are incorporated herein by reference. In some examples, the classification based on these techniques is used in determining entropy measures as described in the Syed reference. For example, each class may be characterized by a range of model parameters for that class (e.g., by partitioning the space of parameters values) or each class be associated with a distribution of the model parameters for that class.
  • Examples of Clinical Applications
  • In some embodiments, characteristics of ECG patterns are associated with events of clinical activity. Some examples of such clinical applications includes using an entropy measure of a fECG signal as an indicator of an inflammation condition, or as an indicator of a cause of an inflammation condition, for example, an infection-based cause of inflammation.
  • In an experimental application of signal processing and analysis techniques described above, the fECG waveforms of 30 recordings discovered a change in the morphology of the heart beat that occurs prior to the development of chorioamnionitis.
  • FIGS. 9A-9C illustrate three classes of QRS complexes classified from a 7-hour dataset collected from a woman who developed chorioamnionitis during labor. FIG. 9D shows the occurrence of each beat during 10-minute intervals timed with respect to the onset of maternal fever of the same patient. Note the consistent appearance of class 1 ECG signals one hour prior to the development of fever.
  • Analyses of the fetal ECG waveforms also show that a measure of entropy—the degree of disorder in the similarity of the morphology of sequences the fetal heart beats—distinguishes those fetuses subject to intra-amniotic infection from those without exposure to infection.
  • FIGS. 10A and 10B illustrate respectively the HRV analysis and entropy analysis of 30 fetal ECG datasets from women with chorioamnionitis and women without infection. As shown in FIG. 10A, the distribution of fetal HRV for fetuses subjected to chorioamnionitis (e.g., exhibiting maternal fever symptom) is not easily distinguishable from that of fetuses in an uninfected intrauterine environment. In comparison, FIG. 10B shows that, when the entropy of the fetal ECG signal is calculated for the same set of fetal ECG data, fetuses subjected to chorioamnionitis are bimodally distributed with respect to entropy, whereas fetuses in an uninfected environment are essentially normally distributed. In other words, an ECG waveform having a very low (e.g., 0) or very high (e.g., 4) entropy indicates a higher probability of developing chorioamnionitis. In some examples, the distributions of observed entropy measures in two known classes of patients (e.g., condition present versus normal) are used to form a likelihood ratio test to classify a patient based on an observed entropy.
  • In some examples, different patterns of electrophysiological behaviors can be correlated with medical conditions using specific biochemical markers of such conditions, e.g., markers of inflammation and brain injury measured from fetal umbilical cord collected from the patient. Umbilical cord blood interleukin-6, for example, is significantly elevated in fetuses that develop sepsis compared with fetuses that do not develop sepsis. Cord blood levels of IL-6 greater than 108.5 pg/ml are considered 95% sensitive and 100% specific for neonatal sepsis.
  • FIG. 11 shows an association between the morphologic entropy of the fetal ECG and fetal umbilical cord serum interleukin-8 (IL-8) levels. Increasing levels of IL-8 are correlated (e.g., having a substantially linear relationship) with increasing disorder in the fetal ECG morphology. One possible explanation of this correlation is that an in-utero fetal inflammation/infection is associated with quantitative changes in the fetal ECG, reflecting altered electrophysiological signaling at the level of the fetal brainstem, fetal myocardium, or both.
  • Another related application relates to using characteristics of ECG signals to discriminate between different possible causes of medical conditions. Various causes of diseases may induce changes in ECG morphology through different mechanisms, which may in turn lead to distinguishable patterns in ECG morphologies. For example, infection, which is one explanation for inflammation, may induce a morphological change in fetal ECG signals through brain stem and myocardium level; while preeclampsia (pregnancy-induced hypertension) is likely to affect the ECG morphologies through mechanism of placental failure. The various presentations of ECG morphologies can therefore be used as a basis for discriminating between different causes of certain diseases.
  • In some embodiments, the feature extractor 253 performs signal analysis that is not necessarily related to ECG signals. For example, muscle signals are detected using the surface electrodes or conventional pressure sensors for contractions, and timing and intensity of uterine contractions are estimated. This approach has an advantage of providing a single monitoring device being applied to the mother, while providing multiple clinically-relevant signals.
  • In some embodiments, the fetal monitoring system 100 may incorporate functions of other medical diagnostic tools to enhance fetal ECG detection and/or assist clinical evaluations. For example, a maternal reference signal can be obtained using other sensing modes, such as ultrasound, imaging, and blood pressure sensing, to facilitate fetal ECG extraction. Also, histological and pathological data of a patient can be assessed in conjunction with ECG data to detect inflammation and neuronal injury before the onset of permanent disability.
  • It is to be understood that the foregoing description is intended to illustrate and not to limit the scope of the invention, which is defined by the scope of the appended claims. Other embodiments are within the scope of the following claims.

Claims (17)

1-28. (canceled)
29. A fetal monitor, comprising:
a garment adapted for wearing around a torso of a pregnant female; and
a plurality of electrodes associated with the garment such that, when the garment is disposed around the torso, at least one physiological parameter of the fetus is detected regardless of the position of the fetus within the pregnant female.
30. The fetal monitor of claim 29 wherein the physiological parameter is fetal heart rate, fetal brain activity, fetal body position, or a combination thereof
31. The fetal monitor of claim 29 wherein the plurality of electrodes comprise one or more dry electrodes.
32. The fetal monitor of claim 29 wherein the plurality of electrodes comprise one or more gel-adhesive electrodes.
33. The fetal monitor of claim 29 wherein the plurality of electrodes comprise at least one dry electrode and at least one gel-adhesive electrode.
34. The fetal monitor of claim 29 further comprising electronics that receives a collecting electrode signal from at least one of the plurality of electrodes, receives a reference electrode signal from at least another one of the plurality of electrodes, and produces a lead signal based on the received collecting and reference electrode signals.
35. The fetal monitor of claim 34 wherein the lead signal produced by the electronics comprises a voltage differential between the received collecting and reference electrode signals.
36. The fetal monitor of claim 34 wherein the electronics comprises an amplifier, each of the received collecting and reference electrode signals being an input to the amplifier and the lead signal being an output of the amplifier.
37. The fetal monitor of claim 34 wherein the electronics receives a maternal reference electrode signal from at least one of the plurality of electrodes.
38. The fetal monitor of claim 34 wherein each of the at least one of the plurality of electrodes producing the collecting electrode signal is referred to as a collecting electrode and each of the at least one of the plurality of electrodes producing the reference electrode signal is referred to as a reference electrode, and wherein at least one of the collecting electrodes and at least one of the reference electrodes are disposed on different sides of the torso when the garment is worn around the torso of the pregnant female.
39. The fetal monitor of claim 38 wherein one or more of the collecting electrodes are disposed within an abdominal region of the torso and one or more of the reference electrodes are disposed within a lumbar region of the torso.
40. The fetal monitor of claim 38 wherein one or more of the collecting electrodes are disposed within a lumbar region of the torso and one or more of the reference electrodes are disposed within an abdominal region of torso.
41. The fetal monitor of claim 38 wherein one or more of the collecting electrodes are disposed on a left side of the torso and one or more of the reference electrodes are disposed on a right side of the torso.
42. The fetal monitor of claim 38 wherein one or more of the collecting electrodes are disposed on a right side of the torso and one or more of the reference electrodes are disposed on a left side of the torso.
43. The fetal monitor of claim 38 wherein one or more of the collecting electrodes are disposed on a left side of the torso, and one or more of the reference electrodes are disposed within an abdominal region of the torso, the lumbar region of the torso, or a combination thereof.
44. The fetal monitor of claim 38 wherein one or more of the collecting electrodes are disposed on a right side of the torso, and one or more of the reference electrodes are disposed within an abdominal region of the torso, the lumbar region of the torso, or a combination thereof.
US13/249,812 2008-04-15 2011-09-30 Fetal ecg monitoring Abandoned US20120083676A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/249,812 US20120083676A1 (en) 2008-04-15 2011-09-30 Fetal ecg monitoring

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US4505508P 2008-04-15 2008-04-15
US10080708P 2008-09-29 2008-09-29
US12/424,046 US7949389B2 (en) 2008-04-15 2009-04-15 Fetal ECG monitoring
US13/113,293 US20120016209A1 (en) 2008-04-15 2011-05-23 Fetal ecg monitoring
US13/249,812 US20120083676A1 (en) 2008-04-15 2011-09-30 Fetal ecg monitoring

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US13/113,293 Continuation US20120016209A1 (en) 2008-04-15 2011-05-23 Fetal ecg monitoring

Publications (1)

Publication Number Publication Date
US20120083676A1 true US20120083676A1 (en) 2012-04-05

Family

ID=41164560

Family Applications (3)

Application Number Title Priority Date Filing Date
US12/424,046 Active 2029-10-03 US7949389B2 (en) 2008-04-15 2009-04-15 Fetal ECG monitoring
US13/113,293 Abandoned US20120016209A1 (en) 2008-04-15 2011-05-23 Fetal ecg monitoring
US13/249,812 Abandoned US20120083676A1 (en) 2008-04-15 2011-09-30 Fetal ecg monitoring

Family Applications Before (2)

Application Number Title Priority Date Filing Date
US12/424,046 Active 2029-10-03 US7949389B2 (en) 2008-04-15 2009-04-15 Fetal ECG monitoring
US13/113,293 Abandoned US20120016209A1 (en) 2008-04-15 2011-05-23 Fetal ecg monitoring

Country Status (8)

Country Link
US (3) US7949389B2 (en)
EP (1) EP2276401A4 (en)
JP (1) JP2011516238A (en)
KR (1) KR20110049744A (en)
BR (1) BRPI0907279A8 (en)
CA (1) CA2721622C (en)
IL (1) IL208650A (en)
WO (1) WO2009146181A1 (en)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120108989A1 (en) * 2009-07-06 2012-05-03 Heard Systems Pty Ltd Non-invasively measuring physiological process
US20120150010A1 (en) * 2009-07-06 2012-06-14 Monica Healthcare Limited Monitoring uterine activity
US8892181B2 (en) 2011-10-21 2014-11-18 Mindchild Medical, Inc. Non-invasive fetal monitoring
CN104382585A (en) * 2014-11-25 2015-03-04 蒋淑清 Device, system and method for portably detecting vital signs of pregnant woman
US20150148695A1 (en) * 2012-06-05 2015-05-28 Cheetah Medical, Inc. Method and system for assessing likelihood of sepsis
US20160183873A1 (en) * 2014-12-31 2016-06-30 Hon Hai Precision Industry Co., Ltd. Fetal health monitoring belt
WO2016126639A1 (en) * 2015-02-02 2016-08-11 One Million Metrics Corp. System and method for monitoring safety and productivity of physical tasks
US10772538B1 (en) 2014-03-17 2020-09-15 One Million Metrics Corp. System and method for monitoring safety and productivity of physical tasks
US11207017B2 (en) * 2016-12-13 2021-12-28 King Abdullah University Of Science And Technology System and method for non-invasive extraction of fetal electrocardiogram signals
WO2023102419A1 (en) * 2021-12-01 2023-06-08 Marani Health, Inc. Apparatus for non-invasive acquisition of maternal and/or fetal physiological signals

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8636676B2 (en) * 2005-06-07 2014-01-28 Perigen, Inc Method and apparatus for providing information related to labor progress for an obstetrics patient
US9805164B2 (en) * 2006-05-01 2017-10-31 Perigen, Inc. Method and apparatus for providing contraction information during labour
US10134490B2 (en) 2006-05-01 2018-11-20 Perigen, Inc. Method and system for monitoring labour progression for an obstetrics patient
CN101835420A (en) * 2007-08-23 2010-09-15 麻省理工学院 Be used for reducing method and apparatus based on the number of active lanes of the epileptic seizure detector of EEG
US20090143650A1 (en) * 2007-11-28 2009-06-04 Regents Of The University Of Minnesota Miniaturized, dermal-adhesive-based device for position-independent, non-invasive fetal monitoring
CA2707312C (en) * 2007-12-10 2016-06-07 Lms Medical Systems Ltd. Method and apparatus for providing contraction information during labour
US20090240158A1 (en) * 2007-12-11 2009-09-24 Lms Medical Systems Ltd User-interface for displaying fetal condition information during labor and apparatus implementing same
WO2009091583A1 (en) * 2008-01-16 2009-07-23 Massachusetts Institute Of Technology Method and apparatus for predicting patient outcomes form a physiological segmentable patient signal
US20100016743A1 (en) * 2008-07-17 2010-01-21 Syed Zeeshan H Identifying Groups of Patients with Similar Physiological Characteristics and Risk Profiles
US10213164B2 (en) * 2008-09-26 2019-02-26 Qualcomm Incorporated Method and apparatus for under-sampled acquisition and transmission of photoplethysmograph (PPG) data and reconstruction of full band PPG data at the receiver
US9579055B1 (en) * 2008-10-17 2017-02-28 Orbital Research Inc. Apparatus for non-invasive fetal biosignal acquisition
EP2464284A4 (en) * 2009-09-29 2014-01-01 Epi Mobile Health Soliutions S Pte Ltd Mobile phone for recording ecg
EP2547261A4 (en) 2010-03-15 2017-07-05 University Of South Florida Electronic catheter stethoscope
JP5645189B2 (en) * 2011-01-26 2014-12-24 公立大学法人奈良県立医科大学 Fetal condition detection abdominal band and fetal condition detection method using the same
CN102090888B (en) * 2011-03-30 2012-07-25 南京大学 Method for separating and extracting fetal electrocardiogram by adopting multi-lead signal fusion mode
US9332919B2 (en) 2011-04-04 2016-05-10 Cardiocity Limited Heart monitoring apparatus
CN102258368B (en) * 2011-04-29 2014-04-02 华南理工大学 Time-domain sparsity linear aliasing blind separation model discrimination method in fetal electrocardiogram detection
WO2013019941A2 (en) * 2011-08-02 2013-02-07 Reproductive Research Technologies, Lp Method and system to monitor, detect, diagnose and predict the separation/rupture of the uterine scar associated with vaginal birth after cesarean procedures
RU2486869C1 (en) * 2012-02-06 2013-07-10 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт медицинских проблем Севера" Сибирского отделения Российской академии медицинских наук (ФГБУ "НИИМПС" СО РАМН) Method of predicting risk of cerebral ischemia development in newborn babies
US20150164404A1 (en) * 2012-05-23 2015-06-18 Convergent Engineering, Inc. System and method for detecting preeclampsia
JP6071260B2 (en) * 2012-06-13 2017-02-01 キヤノン株式会社 Subject information acquisition apparatus and information processing method
JPWO2014002823A1 (en) * 2012-06-29 2016-05-30 日本電気株式会社 Pregnant / fetal electrocardiogram measuring device, pregnant / fetal electrocardiographic measuring system, abdominal band, pregnant / fetal electrocardiographic measuring method and program
WO2014030162A1 (en) * 2012-08-22 2014-02-27 Ben-Gurion University Of The Negev Research & Development Authority Separating clinically relevant sources of electrical activity in ecg signals
US8868164B2 (en) * 2013-03-04 2014-10-21 General Electric Company Fetal monitoring device and method
RU2645930C2 (en) * 2013-06-01 2018-02-28 Хелсуотч Лтд. Wearable fetal monitoring system having textile electrodes
US9295397B2 (en) 2013-06-14 2016-03-29 Massachusetts Institute Of Technology Method and apparatus for beat-space frequency domain prediction of cardiovascular death after acute coronary event
US20140378855A1 (en) 2013-06-25 2014-12-25 The Research Foundation For The State University Of New York Apparatus and method for feature extraction and classification of fetal heart rate
CN105592786A (en) * 2013-08-08 2016-05-18 R·S·盖思特 Wireless pregnancy monitor
CN104434310B (en) * 2013-09-13 2017-06-23 深圳迈瑞生物医疗电子股份有限公司 Custodial care facility and its performance parameters improved method, system
GB2521342B (en) 2013-10-17 2016-08-03 Monica Healthcare Ltd Apparatus and method for detecting an abdominal electrophysiological signal
US10076258B2 (en) 2013-11-01 2018-09-18 Boston Scientific Scimed, Inc. Cardiac mapping using latency interpolation
US9687167B2 (en) * 2014-03-11 2017-06-27 Boston Scientific Scimed, Inc. Medical devices for mapping cardiac tissue
CN103876731B (en) * 2014-03-25 2016-01-13 电子科技大学 A kind of Fetal ECG signal extracting device and method
JP6324490B2 (en) 2014-03-26 2018-05-16 国立大学法人東北大学 Fetal state estimation device, fetal state estimation method, and fetal state estimation program
JP2016016042A (en) * 2014-07-07 2016-02-01 日本電信電話株式会社 electrode
JP6692814B2 (en) * 2014-12-12 2020-05-13 コーニンクレッカ フィリップス エヌ ヴェKoninklijke Philips N.V. Device and method for measuring a physiological characteristic of a subject
US9392952B1 (en) * 2015-03-10 2016-07-19 Nuvo Group Ltd. Systems, apparatus and methods for sensing fetal activity
ES2752625T3 (en) * 2015-10-23 2020-04-06 Cleveland Clinic Found Systems and methods for automated addressing of electrical elements
JP2018537187A (en) * 2015-11-30 2018-12-20 コーニンクレッカ フィリップス エヌ ヴェKoninklijke Philips N.V. Fetal position monitoring system and method
CN109068986B (en) 2016-04-01 2021-08-06 奥丽特婴儿保健公司 Fetal health data monitoring
KR102175665B1 (en) * 2016-09-26 2020-11-06 고려대학교 산학협력단 Smart fetal health analysis apparatus and the method for controlling the same
EP3589200A4 (en) * 2017-02-28 2021-03-31 Mayo Foundation for Medical Education and Research Systems and methods for fetal monitoring
CN106991291B (en) * 2017-04-14 2020-01-10 北京工业大学 Computer simulation conversion method for real-time conversion of fetal electrocardiosignals into fetal sounds
US11510607B2 (en) 2017-05-15 2022-11-29 Bloom Technologies NV Systems and methods for monitoring fetal wellbeing
US11576622B2 (en) 2017-07-19 2023-02-14 Bloom Technologies NV Systems and methods for monitoring uterine activity and assessing pre-term birth risk
USD868978S1 (en) 2018-04-18 2019-12-03 Owlet Baby Care, Inc. Maternal belly band
USD866987S1 (en) 2018-04-18 2019-11-19 Owlet Baby Care, Inc. Fabric electrode assembly
USD877344S1 (en) 2018-04-18 2020-03-03 Owlet Baby Care, Inc. Maternal band processing unit
USD866199S1 (en) 2018-04-18 2019-11-12 Owlet Baby Care, Inc. Fabric electrode assembly
US11298065B2 (en) 2018-12-13 2022-04-12 Owlet Baby Care, Inc. Fetal heart rate extraction within a processor constrained environment
EP3975830A4 (en) 2019-05-31 2023-07-05 Owlet Baby Care, Inc. Prenatal monitoring device
US11826129B2 (en) 2019-10-07 2023-11-28 Owlet Baby Care, Inc. Heart rate prediction from a photoplethysmogram
WO2021211692A1 (en) * 2020-04-15 2021-10-21 Owlet Baby Care Inc. Apparatus and method for determining fetal movement
US11744501B2 (en) 2020-05-07 2023-09-05 GE Precision Healthcare LLC Multi-sensor patch
US20230200746A1 (en) * 2021-12-23 2023-06-29 Marani Health, Inc. System for acquisition and analysis of maternal and/or fetal physiological signals

Citations (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4781200A (en) * 1985-10-04 1988-11-01 Baker Donald A Ambulatory non-invasive automatic fetal monitoring system
US5353793A (en) * 1991-11-25 1994-10-11 Oishi-Kogyo Company Sensor apparatus
US5623939A (en) * 1994-05-19 1997-04-29 Board Of Regents, University Of Texas System Method and apparatus for analyzing uterine electrical activity from surface measurements for obstetrical diagnosis
US5807271A (en) * 1997-04-14 1998-09-15 Tayebi; Sean Fetal heartbeat and uterine contraction
US5846558A (en) * 1996-03-19 1998-12-08 Minnesota Mining And Manufacturing Company Ionically conductive adhesives prepared from zwitterionic materials and medical devices using such adhesives
US6171263B1 (en) * 1994-11-24 2001-01-09 The Institute Of Respiratory Medicine Limited Foetal circulatory impedance monitor
US20040073094A1 (en) * 2002-10-15 2004-04-15 Baker Donald A. Fetal monitoring systems with ambulatory patient units and telemetric links for improved uses
US6751498B1 (en) * 1999-03-15 2004-06-15 The Johns Hopkins University Apparatus and method for non-invasive, passive fetal heart monitoring
US6785569B2 (en) * 2001-09-07 2004-08-31 Orbital Research Dry physiological recording electrode
US20050267377A1 (en) * 2004-05-28 2005-12-01 Dorothee Marossero Maternal-fetal monitoring system
US20100076330A1 (en) * 2007-01-23 2010-03-25 Tohoku Techno Arch Co., Ltd. Fetus electrocardiogram signal measuring method and its device
US20100185108A1 (en) * 2007-07-20 2010-07-22 Vullings Rik Fetal monitoring
US7797039B2 (en) * 2003-10-03 2010-09-14 Mega Elektroniikka Oy Method for recognizing the heartbeat and for calculating quantities acquired from the heartbeat
US7869863B2 (en) * 2008-01-10 2011-01-11 The Johns Hopkins University Apparatus and method for non-invasive, passive fetal heart monitoring
US20110218413A1 (en) * 2010-03-02 2011-09-08 Yixiang Wang Method and Apparatus for Non-invasive Fetal Oximetry
US8160692B2 (en) * 2006-12-11 2012-04-17 University Of Florida Research Foundation, Inc. System and method for analyzing progress of labor and preterm labor
US8175692B2 (en) * 2005-01-31 2012-05-08 Tohoku University Electrocardiogram signal-processing method and electrocardiogram signal-processing device

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3703168A (en) * 1970-03-30 1972-11-21 Richard D Frink Fetal heart monitor with particular signal conditioning means
DE2716739C3 (en) * 1977-04-14 1980-06-26 Biotronik Mess- Und Therapiegeraete Gmbh & Co Ingenieurbuero Berlin, 1000 Berlin Method for the detection of signals
IL82698A0 (en) 1987-05-29 1987-11-30 Univ Ramot Method and apparatus for indicating repetition intervals of a specified component of a composite electrical signal,particularly useful for displaying fetal r-waves
US5846189A (en) * 1989-09-08 1998-12-08 Pincus; Steven M. System for quantifying asynchrony between signals
US5372139A (en) 1991-06-24 1994-12-13 Paul Benjamin Crilly Method for suppressing a maternal electrocardiogram signal from a fetal electrocardiogram signal obtained with invasive and non-invasive techniques using an almost pure maternal electrocardiogram signal as a trigger
US5713367A (en) 1994-01-26 1998-02-03 Cambridge Heart, Inc. Measuring and assessing cardiac electrical stability
US5666959A (en) * 1995-08-30 1997-09-16 British Technology Group Limited Fetal heart rate monitoring
GB2342449B (en) * 1998-12-22 2000-09-20 Neoventa Medical Ab Device for reducing signal noise in a fetal ECG signal
JP2002538872A (en) * 1999-03-15 2002-11-19 ザ ジョンズ ホプキンズ ユニバーシティ Apparatus and method for non-invasively and passively monitoring a fetal heart
JP2004129788A (en) * 2002-10-09 2004-04-30 Nippon Koden Corp Device for processing biological information
EP1941832B1 (en) * 2003-10-14 2010-10-06 Monica Healthcare Limited Fetal surveillance
US7314451B2 (en) 2005-04-25 2008-01-01 Earlysense Ltd. Techniques for prediction and monitoring of clinical episodes
EP1568316A1 (en) * 2004-02-24 2005-08-31 Neoventa medical AB Assessment of fetal reactivity by fetal heart rate analysis
US8255238B2 (en) 2005-01-03 2012-08-28 Airstrip Ip Holdings, Llc System and method for real time viewing of critical patient data on mobile devices
WO2006081447A2 (en) 2005-01-27 2006-08-03 The Board Of Trustees Of The University Of Illinois Blind adaptive filter extraction of fetal electrocardiogram signal estimate
US7942818B2 (en) * 2006-02-01 2011-05-17 University Of Florida Research Foundation, Inc. Obstetric analgesia system
US20070260151A1 (en) * 2006-05-03 2007-11-08 Clifford Gari D Method and device for filtering, segmenting, compressing and classifying oscillatory signals

Patent Citations (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4781200A (en) * 1985-10-04 1988-11-01 Baker Donald A Ambulatory non-invasive automatic fetal monitoring system
US5353793A (en) * 1991-11-25 1994-10-11 Oishi-Kogyo Company Sensor apparatus
US5623939A (en) * 1994-05-19 1997-04-29 Board Of Regents, University Of Texas System Method and apparatus for analyzing uterine electrical activity from surface measurements for obstetrical diagnosis
US6171263B1 (en) * 1994-11-24 2001-01-09 The Institute Of Respiratory Medicine Limited Foetal circulatory impedance monitor
US5846558A (en) * 1996-03-19 1998-12-08 Minnesota Mining And Manufacturing Company Ionically conductive adhesives prepared from zwitterionic materials and medical devices using such adhesives
US5807271A (en) * 1997-04-14 1998-09-15 Tayebi; Sean Fetal heartbeat and uterine contraction
US6751498B1 (en) * 1999-03-15 2004-06-15 The Johns Hopkins University Apparatus and method for non-invasive, passive fetal heart monitoring
US6785569B2 (en) * 2001-09-07 2004-08-31 Orbital Research Dry physiological recording electrode
US20040073094A1 (en) * 2002-10-15 2004-04-15 Baker Donald A. Fetal monitoring systems with ambulatory patient units and telemetric links for improved uses
US7797039B2 (en) * 2003-10-03 2010-09-14 Mega Elektroniikka Oy Method for recognizing the heartbeat and for calculating quantities acquired from the heartbeat
US20050267377A1 (en) * 2004-05-28 2005-12-01 Dorothee Marossero Maternal-fetal monitoring system
US8175692B2 (en) * 2005-01-31 2012-05-08 Tohoku University Electrocardiogram signal-processing method and electrocardiogram signal-processing device
US8160692B2 (en) * 2006-12-11 2012-04-17 University Of Florida Research Foundation, Inc. System and method for analyzing progress of labor and preterm labor
US20100076330A1 (en) * 2007-01-23 2010-03-25 Tohoku Techno Arch Co., Ltd. Fetus electrocardiogram signal measuring method and its device
US20100185108A1 (en) * 2007-07-20 2010-07-22 Vullings Rik Fetal monitoring
US7869863B2 (en) * 2008-01-10 2011-01-11 The Johns Hopkins University Apparatus and method for non-invasive, passive fetal heart monitoring
US20110218413A1 (en) * 2010-03-02 2011-09-08 Yixiang Wang Method and Apparatus for Non-invasive Fetal Oximetry

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Sameni et al. "Electrode Selection for Noninvasive Fetal Electrocardiogram Extraction using Mutual Information Criteria." 2006. *
Vrins et al. "Abdominal Electrodes Analysis by Statistical Processing for Fetal Electrocardiogram Extraction." Proceedings of the Second International Conference. 2004. *

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120150010A1 (en) * 2009-07-06 2012-06-14 Monica Healthcare Limited Monitoring uterine activity
US8652063B2 (en) * 2009-07-06 2014-02-18 Heard Systems Pty Ltd Non-invasively measuring physiological process
US20120108989A1 (en) * 2009-07-06 2012-05-03 Heard Systems Pty Ltd Non-invasively measuring physiological process
US9968291B2 (en) * 2009-07-06 2018-05-15 Monica Healthcare Limited Monitoring uterine activity
US8892181B2 (en) 2011-10-21 2014-11-18 Mindchild Medical, Inc. Non-invasive fetal monitoring
US9839396B2 (en) * 2012-06-05 2017-12-12 Cheetah Medical, Inc. Method and system for assessing likelihood of sepsis
US20150148695A1 (en) * 2012-06-05 2015-05-28 Cheetah Medical, Inc. Method and system for assessing likelihood of sepsis
US10772538B1 (en) 2014-03-17 2020-09-15 One Million Metrics Corp. System and method for monitoring safety and productivity of physical tasks
US9833197B1 (en) 2014-03-17 2017-12-05 One Million Metrics Corp. System and method for monitoring safety and productivity of physical tasks
US10674965B2 (en) 2014-03-17 2020-06-09 One Million Metrics Corp. System and method for monitoring safety and productivity of physical tasks
US11406289B2 (en) 2014-03-17 2022-08-09 One Million Metrics Corp. System and method for monitoring safety and productivity of physical tasks
CN104382585A (en) * 2014-11-25 2015-03-04 蒋淑清 Device, system and method for portably detecting vital signs of pregnant woman
US20160183873A1 (en) * 2014-12-31 2016-06-30 Hon Hai Precision Industry Co., Ltd. Fetal health monitoring belt
WO2016126639A1 (en) * 2015-02-02 2016-08-11 One Million Metrics Corp. System and method for monitoring safety and productivity of physical tasks
US11207017B2 (en) * 2016-12-13 2021-12-28 King Abdullah University Of Science And Technology System and method for non-invasive extraction of fetal electrocardiogram signals
WO2023102419A1 (en) * 2021-12-01 2023-06-08 Marani Health, Inc. Apparatus for non-invasive acquisition of maternal and/or fetal physiological signals

Also Published As

Publication number Publication date
EP2276401A4 (en) 2014-02-05
IL208650A (en) 2013-09-30
US7949389B2 (en) 2011-05-24
KR20110049744A (en) 2011-05-12
BRPI0907279A2 (en) 2016-11-16
CA2721622C (en) 2016-10-11
IL208650A0 (en) 2010-12-30
US20090259133A1 (en) 2009-10-15
CA2721622A1 (en) 2009-12-03
BRPI0907279A8 (en) 2018-12-18
EP2276401A1 (en) 2011-01-26
JP2011516238A (en) 2011-05-26
WO2009146181A1 (en) 2009-12-03
US20120016209A1 (en) 2012-01-19

Similar Documents

Publication Publication Date Title
US7949389B2 (en) Fetal ECG monitoring
US8892181B2 (en) Non-invasive fetal monitoring
US20130102856A1 (en) Non-invasive detection of fetal or maternal illness
Behar et al. A practical guide to non-invasive foetal electrocardiogram extraction and analysis
Jezewski et al. Determination of fetal heart rate from abdominal signals: evaluation of beat-to-beat accuracy in relation to the direct fetal electrocardiogram
Hasan et al. Detection and processing techniques of FECG signal for fetal monitoring
Signorini et al. Monitoring fetal heart rate during pregnancy: contributions from advanced signal processing and wearable technology
Fanelli et al. Quantitative assessment of fetal well-being through CTG recordings: a new parameter based on phase-rectified signal average
US7333850B2 (en) Maternal-fetal monitoring system
JP5271718B2 (en) How to identify fetal and maternal ECGs across multiple time segments
Rooijakkers et al. Feasibility study of a new method for low-complexity fetal movement detection from abdominal ECG recordings
Namadurai et al. Multifractal analysis of uterine electromyography signals for the assessment of progression of pregnancy in term conditions
Galli et al. Automatic optimization of multichannel electrode configurations for robust fetal heart rate detection by blind source separation
Biloborodova et al. Fetal ECG signal processing and identification of hypoxic pregnancy conditions in-utero
Peters et al. Beat-to-beat heart rate detection in multi-lead abdominal fetal ECG recordings
Tian et al. A comprehensive evaluation of the predictive abilities of fetal electrocardiogram-derived parameters during labor in newborn acidemia: our institutional experience
Rooijakkers et al. Fetal movement detection based on QRS amplitude variations in abdominal ECG recordings
Fanelli TeleFetal Care: development of a wearable system for fetal monitoring during pregnancy
Fanelli et al. A smart wearable prototype for fetal monitoring
Ghosh et al. Detection and analysis of fetal movements using an acoustic sensor-based wearable monitor
Marzbanrad Modeling fetal cardiac valve intervals and fetal-maternal interactions
Vardhini et al. Empirical mode decomposition based detrended fluctuation analysis of uterine electromyography signals in term conditions
Sowmya et al. Detecting anomalies in fetal electrocardiogram records using deep learning models
Manap Fetal QT Interval Detection from Abdominal ECG Signals by Using Iterative Independent Component Analysis
Fatima Azzahra Fetal QT interval detection from abdominal ECG signals by using iterative independent component analysis/Fatima Azzahra Manap

Legal Events

Date Code Title Description
AS Assignment

Owner name: E-TROLZ, INC., MASSACHUSETTS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:WARD, JAY;REEL/FRAME:026999/0397

Effective date: 20090413

Owner name: TUFTS MEDICAL CENTER, INC., MASSACHUSETTS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:WOLFBERG, ADAM J.;REEL/FRAME:026999/0279

Effective date: 20090414

Owner name: MASSACHUSETTS INSTITUTE OF TECHNOLOGY, MASSACHUSET

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CLIFFORD, GARI D.;REEL/FRAME:026999/0330

Effective date: 20110302

AS Assignment

Owner name: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF

Free format text: CONFIRMATORY LICENSE;ASSIGNOR:TUFTS MEDICAL CENTER;REEL/FRAME:029156/0462

Effective date: 20121004

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION